TrialBlood2019

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.

Shigeru Kusumoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.